Limits...
Meningococcal disease in Asia: an under-recognized public health burden.

Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M - Epidemiol. Infect. (2011)

Bottom Line: This suggests that meningococcal disease in some Asian countries may be under-recognized, with a need to introduce/improve existing surveillance and case identification systems.Nevertheless, in some developing Asian countries, the disease burden may be significant.Multivalent meningococcal conjugate vaccines offer new opportunities in the region for reducing the meningococcal disease burden.

View Article: PubMed Central - PubMed

Affiliation: GlaxoSmithKline Biologicals Group of Companies, Wavre, Belgium.

ABSTRACT
A literature search traced existing information on meningococcal disease in Asia. Reviewed data describing the epidemiology of meningococcal disease in Asia are incomplete, due in part to absence of surveillance in many countries, poor bacterial detection methods and social and healthcare barriers to disease reporting. This suggests that meningococcal disease in some Asian countries may be under-recognized, with a need to introduce/improve existing surveillance and case identification systems. Nevertheless, in some developing Asian countries, the disease burden may be significant. Serogroup A meningococcal epidemics are responsible for high morbidity and mortality in some countries and continue to be an ongoing threat, particularly in developing countries. There is an increasing role played by serogroups C, Y, and W-135 in invasive disease, indicating evolving meningococcal disease epidemiology in some countries. Multivalent meningococcal conjugate vaccines offer new opportunities in the region for reducing the meningococcal disease burden.

Show MeSH

Related in: MedlinePlus

Serogroup distribution of meningococcal disease cases in Asian countries with available data (map outline reproduced from [48]). %=percentage of serogroupable isolates.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3105449&req=5

fig001: Serogroup distribution of meningococcal disease cases in Asian countries with available data (map outline reproduced from [48]). %=percentage of serogroupable isolates.

Mentions: At the time of writing 11 of the 20 Asian countries we investigated (India, Pakistan, Bangladesh, Indonesia, Vietnam, Cambodia, Laos, Mongolia, Myanmar, Sri Lanka, Nepal), representing a total population of about 2 million [15], were eligible for funding from the GAVI Alliance [16]. All 11 countries currently receive GAVI support. Six of these countries (India, Indonesia, Mongolia, Nepal, Pakistan, Vietnam) have suffered major serogroup A (or C in Vietnam) meningococcal epidemics in the last 30 years (Table 1). Available data suggest that these poorer countries represent a disproportionately high fraction of the overall meningococcal disease burden in Asia. The population incidences of meningococcal disease in countries with available data are given in Table 2. Serogroup distributions by country are given in Figure 1. While some published data were available for GAVI-eligible countries, these were limited and of varying quality.


Meningococcal disease in Asia: an under-recognized public health burden.

Vyse A, Wolter JM, Chen J, Ng T, Soriano-Gabarro M - Epidemiol. Infect. (2011)

Serogroup distribution of meningococcal disease cases in Asian countries with available data (map outline reproduced from [48]). %=percentage of serogroupable isolates.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3105449&req=5

fig001: Serogroup distribution of meningococcal disease cases in Asian countries with available data (map outline reproduced from [48]). %=percentage of serogroupable isolates.
Mentions: At the time of writing 11 of the 20 Asian countries we investigated (India, Pakistan, Bangladesh, Indonesia, Vietnam, Cambodia, Laos, Mongolia, Myanmar, Sri Lanka, Nepal), representing a total population of about 2 million [15], were eligible for funding from the GAVI Alliance [16]. All 11 countries currently receive GAVI support. Six of these countries (India, Indonesia, Mongolia, Nepal, Pakistan, Vietnam) have suffered major serogroup A (or C in Vietnam) meningococcal epidemics in the last 30 years (Table 1). Available data suggest that these poorer countries represent a disproportionately high fraction of the overall meningococcal disease burden in Asia. The population incidences of meningococcal disease in countries with available data are given in Table 2. Serogroup distributions by country are given in Figure 1. While some published data were available for GAVI-eligible countries, these were limited and of varying quality.

Bottom Line: This suggests that meningococcal disease in some Asian countries may be under-recognized, with a need to introduce/improve existing surveillance and case identification systems.Nevertheless, in some developing Asian countries, the disease burden may be significant.Multivalent meningococcal conjugate vaccines offer new opportunities in the region for reducing the meningococcal disease burden.

View Article: PubMed Central - PubMed

Affiliation: GlaxoSmithKline Biologicals Group of Companies, Wavre, Belgium.

ABSTRACT
A literature search traced existing information on meningococcal disease in Asia. Reviewed data describing the epidemiology of meningococcal disease in Asia are incomplete, due in part to absence of surveillance in many countries, poor bacterial detection methods and social and healthcare barriers to disease reporting. This suggests that meningococcal disease in some Asian countries may be under-recognized, with a need to introduce/improve existing surveillance and case identification systems. Nevertheless, in some developing Asian countries, the disease burden may be significant. Serogroup A meningococcal epidemics are responsible for high morbidity and mortality in some countries and continue to be an ongoing threat, particularly in developing countries. There is an increasing role played by serogroups C, Y, and W-135 in invasive disease, indicating evolving meningococcal disease epidemiology in some countries. Multivalent meningococcal conjugate vaccines offer new opportunities in the region for reducing the meningococcal disease burden.

Show MeSH
Related in: MedlinePlus